Original Article

You have full text access to this OnlineOpen article

Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896)

A trial of the Eastern Cooperative Oncology Group

  1. David J. Vaughn M.D.1,†,*,
  2. Judith Manola M.S.2,
  3. Robert Dreicer M.D.3,
  4. William See M.D.4,
  5. Ralph Levitt M.D.5,
  6. George Wilding M.D.6

Article first published online: 19 AUG 2002

DOI: 10.1002/cncr.10782

Issue

Cancer

Cancer

Volume 95, Issue 5, pages 1022–1027, 1 September 2002

Additional Information

How to Cite

Vaughn, D. J., Manola, J., Dreicer, R., See, W., Levitt, R. and Wilding, G. (2002), Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896). Cancer, 95: 1022–1027. doi: 10.1002/cncr.10782

Author Information

  1. 1

    Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania

  2. 2

    Dana–Farber Cancer Institute, Boston, Massachusetts

  3. 3

    Cleveland Clinic Foundation, Cleveland, Ohio

  4. 4

    Medical College of Wisconsin, Milwaukee, Wisconsin

  5. 5

    Roger Marris Cancer Center, Fargo, North Dakota

  6. 6

    University of Wisconsin, Madison, Wisconsin

  1. †

    Fax: (215) 662–7804

*Abramson Cancer Center, University of Pennsylvania, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104

Publication History

  1. Issue published online: 19 AUG 2002
  2. Article first published online: 19 AUG 2002
  3. Manuscript Accepted: 3 APR 2002
  4. Manuscript Revised: 13 MAR 2002
  5. Manuscript Received: 10 JAN 2002

Funded by

  • Public Health Service. Grant Numbers: CA23318, CA66636, CA21115, CA15488, CA21076, CA13650
  • National Institutes of Health
  • Department of Health and Human Services

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (74K)

REFERENCES

  • 1
    Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002; 52: 23–47.
    Direct Link:
  • 2
    Loehrer PJ Sr., Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group study. J Clin Oncol. 1992; 10: 1066–1073.
  • 3
    Von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J Clin Oncol. 2000; 17: 3068–3077.
  • 4
    Waxman J, Barton C. Carboplatin-based chemotherapy for bladder cancer. Cancer Treat Rev. 1993; 19 (supp C): 21–25.
  • 5
    Calvert AH, Newell DR, Grumbell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989; 7: 1748–1756.
  • 6
    Small EJ, Fippin LJ, Ernest ML, Carroll PR. A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer. 1996; 78: 1775–1780.
    Direct Link:
  • 7
    Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a Phase II trial of the Eastern Cooperative Oncology Group (E1892). J Clin Oncol. 1994; 12: 2264–2270.
  • 8
    Dreicer R, Gustin DM, See WA, Williams RD. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol. 1996; 156: 1606–1608.
  • 9
    Vaughn DJ, Malkowicz SB, Zoltick B, et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol. 1998; 16: 255–260.
  • 10
    Redman BG, Smith DC, Flaherty L, Du W, Hussain M. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol. 1998; 16: 1844–1848.
  • 11
    Pycha A, Grbovic M, Posch B, et al. Paclitaxel and carboplatin in patients with metastatic transitional cell carcinoma of the urinary tract. Urology. 1999; 53: 510–515.
  • 12
    Small EJ, Lew D, Redman BG, et al. Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol. 2000; 18: 2537–2544.
  • 13
    Jellife RW. Creatinine clearance: bedside estimate. Ann Intern Med. 1973; 79: 604–605.
  • 14
    Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome to chemotherapy. J Clin Oncol. 1999; 17: 3173–3181.
View Full Article (HTML) Get PDF (74K)